TLR2 and neoplasm: LR2 activation promotes tumor progression and is linked to patient survival and chemotherapy response in pancreatic ductal adenocarcinoma.543 Although preclinical results are encouraging, clinical trials assessing TLR2 inhibitors in solid tumors are still missing.